Notícias e Atividades da Corcept Therapeutics

Corcept Therapeutics é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Corcept Therapeutics é uma empresa listada sob o símbolo CORT (US).

Veja o organograma con seus 34 executivos principais

Biografias mais buscadas da Corcept Therapeutics

• Joseph Belanoff, Chief Executive Officer & Director
• Daniel Swisher, Director
• Joshua Murray, Director

Recentes movimentos de executivos em Corcept Therapeutics

• Marc Porter, ingressou na Companhia como Director, Marketing  (Notícia publicada em 8 de maio de 2025).

Criar um alerta
para seguir os movimentos de executivos da Corcept Therapeutics.

Corcept Therapeutics possui 2.350 concorrentes concorrentes Astellas Gene Therapies (Estados Unidos), Eurofins (Luxemburgo) e Lonza (Suíça).

Popular M&A news in Biotecnologia

• Sirius Therapeutics acaba de anunciar uma arrecadação de fundos de 50 milhões de dólares. (publicado em 16 de junho de 2025).
• BioNTech has announced the acquisition of CureVac  (publicado em 12 de junho de 2025).
• SpliceBio acaba de anunciar uma arrecadação de fundos de 135 milhões de dólares. (publicado em 11 de junho de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Sandra Smith - Senior Vice President, Clinical Solutions & Strategic Partnerships da WIRB-Copernicus Group
• Jasbir Seehra - Chief Executive Officer and Chairman of the Board da Keros Therapeutics
• Deepika Verma - Associate Director of Data Science and Digitalization da Wheeler Bio

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Corcept Therapeutics

• Press Releases – Corcept Therapeutics, Incorporated
• Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS) – Corcept Therapeutics, Incorporated
• Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism – Corcept Therapeutics, Incorporated
• Press Releases – Corcept Therapeutics, Incorporated
• Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing’s Syndrome) and Difficult-to-Control Diabetes – Corcept Therapeutics, Incorporated
• Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing’s Syndrome and Provides Corporate Update – Corcept Therapeutics, Incorporated
• Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call – Corcept Therapeutics, Incorporated
• Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update – Corcept Therapeutics, Incorporated
• Press Releases – Corcept Therapeutics, Incorporated
• Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call – Corcept Therapeutics, Incorporated
• View more press releases Close

Redes sociais sobre Corcept Therapeutics

• Corcept Therapeutics na Wikipedia, Google News e Yahoo Finance
• Corcept Therapeutics na LinkedIn, Twitter e YouTube